Over the last couple of decades, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. It is considered to be one of the most important pharmacokinetic properties of a drug.   Bioavailability refers to the proportion of a drug that reaches systemic circulation unaltered, post dose administration. Additionally, it is a direct consequence of the absorption potential of an active pharmaceutical ingredient (API). The bioavailability of a drug is dependent on several factors, such as solubility, route of administration and metabolism of the drug post administration. The following figure provides different factors that have been reported to impact drug bioavailability either directly or indirectly.   To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/198/request-sample.html   Solubility: Thesolubility of a substance refers to its ability to dissolve in a solvent and form a homogeneous system. Drug solubility is considered to be one of the most important factors responsible for enabling a therapeutic intervention to be efficiently distributed via systemic circulation. It is worth highlighting that a drug’s solubility is directly proportional to its bioavailability and hence, is one of the primary parameters that is modified during bioavailability enhancement Permeability: Permeability refers to the ability of a molecule to pass through biological membranes. Similar to solubility, drug permeability plays a key role in its absorption and systemic distribution. Membrane based efflux mechanisms and other structural barriers are the major biological elements responsible for poor permeability of drugs. Permeability of a drug is also proportional to its bioavailability; however, it is possible to improve this characteristic by modifying the physiochemical properties of the drug to render them more suitable for absorption across different types of biological membranes. Molecule Size: Rate of absorption increases inversely with the size of a drug molecule. However, several studies have demonstrated that, absorption mechanisms vary significantly for different sizes of molecules. For instance, larger molecules get absorbed either by endocytosis or facilitated diffusion, whereas smaller molecules are absorbed via aqueous diffusion or through lipid channels. Degree of Ionization: Degree of ionization has a direct impact on drug absorption. Higher degree of ionization of a drug molecule results in poor solubility. As a general rule, basic drugs get ionized in acidic medium and are therefore, poorly soluble in acidic medium. The same rule applies to acidic drugs in basic medium. Formulation: The formulation process involves the addition of certain excipients, which are inactive substances that augment the properties of the drugs. Despite being inactive, these substances can influence drug bioavailability. Concentration: According to Fick’s law of diffusion, higher drug concentration in a tissue microenvironment, leads to higher flux through the membrane, resulting in a high rate of absorption. Dosage Forms: Drugs can be administered into the body via a number of routes, such as oral, transdermal, ocular and intramuscular. However, it is important to note that the mode of administration plays a very significant role in drug bioavailability. Several studies have demonstrated that only intravenous injections offer 100% drug availability in systemic circulation compared to any other route. Physical Forms: The physical form of the drug (solid, liquid or inhalable powder) also affects its rate of absorption. It is worth highlighting that drugs get more absorbed in gaseous form followed by liquid and solid form respectively.   Chemical Nature: The chemical make-up of a drug is also an important determinant of its absorption potential and bioavailability. It has been observed that inorganic salts are more readily absorbed than organic compounds, when administered via the oral route.   Further, given the rapid increase in the number of NCEs with low solubility and considering that this trend persists in the future as well, there is likely to be a surge in the demand for technologies that facilitate bioavailability enhancement. There are a number of technologies which are already available for improving drug bioavailability. Broadly these technologies can be distributed across three main categories, namelyphysical, chemical and biological approaches. However, as pharmacological interventions gradually become more complex and novel drug classes are introduced, further innovation may be required in the development of better bioavailability enhancement techniques / methods.   For additional details, please visit  https://www.rootsanalysis.com/reports/view_document/bioavailability-enhancement-technologies-and-services/198.html or email sales@rootsanalysis.com   You may also be interested in the following titles: RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035 Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035   About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Characterized by high prevalence rate of rare and genetic disorders, and rise in demand for effective novel ATMPs, the cell and gene therapy contract research industry is likely to witness evolutionary advancements, in the coming years.   Roots Analysis has announced the addition of Cell and Gene Therapy CRO Market, 2022-2035” report to its list of offerings.                                                  In order to mitigate the challenges associated with the cell and gene therapies research and development, around 50-60% of the developers prefer to outsource their operations to contract research organizations (CROs), which claim to have the required expertise and experience to leverage their capabilities and yield cost savings opportunities. The aforementioned challenges are believed to be the key factors for driving the outsourcing of research operations to a cell and gene therapy CRO, which claim to be well-aware of the nuances of advanced therapy medicinal products (ATMP) design and development, as well as cell and gene therapy manufacturing process.    Key Market Insights   Presently, more than 105 players claim to offer cell and gene therapy contract research services This segment of the industry is dominated by the presence of mid-sized (51-500 employees) and small (2-51 employees) players, which collectively represent more than 70% of the total CROs in this domain. In addition, about 20% of the firms were founded post 2010.   >40% of the players carry out contract research operations across preclinical and clinical scales Nearly 21% of the total industry stakeholders have the required capabilities for cell and gene therapies at the commercial scale. In addition, 16% CROs are capable of providing contract research services for discovery purposes.   Partnership activity in this domain has increased at a CAGR of over 61%, during 2015- 2022 Acquisitions and mergers emerged as the most popular type of partnership model adopted by industry stakeholders (54%), followed by service agreements (20%). Further, most of the deals were inked by players based in North America (58%).   Over 32 mergers and acquisitions were established in this domain, during the period 2015-2022 It was observed that majority of the deals were intracontinental (72%), involving participants from different countries. Geographical consolidation and portfolio addition were observed to be the major key value drivers of M&A activity, followed by service portfolio and geographical expansion (28%, each).   More than 1,330 clinical trials evaluating cell and gene therapies have been registered worldwide Of the total, close to 79% of the studies are active and recruiting patients, followed by those that have already been completed (7%). It is important to highlight that more than 20% of cell and gene therapy focused-clinical trials are currently in phase II.   North America and Europe are anticipated to capture over 75% of the market share, in 2035 In terms of scale of operation, the current market is driven by clinical operations (55%); this trend is unlikely to change in the foreseen future as well. Further, based on area of expertise, majority of the revenue share (61%) of the overall market in 2035 is likely to be driven by cell therapies.   To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/230/request-sample.html   Key Questions Answered Who are the leading players engaged in offering cell and gene therapy related research services? Which business models are most commonly adopted by biopharmaceutical developers for outsourcing cell and gene therapies? Which partnership models are commonly adopted by stakeholders engaged in this industry? What are the key value drivers of the merger and acquisition activity in the cell and gene therapy market? Which players are likely to partner with cell and gene therapy CROs? Which regions emerged as the key hubs for carrying out clinical studies focused on cell and gene therapies? How is the current and future market opportunity likely to be distributed across key market segments? What are the anticipated future trends related to cell and gene therapy related research services?   The financial opportunity within the cell and gene therapy CROs market has been analyzed across the following segments: Area of Expertise Cell Therapy Gene Therapy   Scale of Operation Preclinical Clinical Drug Discovery   Therapeutic Area Oncological Disorders Neurological Disorders Cardiovascular Disorders Infectious Diseases Metabolic Disorders Autoimmune Disorders Blood Disorders Rare / Genetic Disorders Ophthalmic Disorders Other disorders   Analysis by Geographical Regions North America Europe Asia Pacific Latin America Middle East and North Africa   The report includes profiles of key players (listed below) engaged in the offering CRO services for cell and gene therapies, across both preclinical and clinical scales of operation; each profile features a brief overview of the company, along with details related to its cell and gene therapies-related service portfolio, recent developments, and an informed future outlook. Altasciences Allucent Charles River Laboratories Creative Biolabs IQVIA Medpace  PPD Precision for Medicine QPS Accelera Evotec ICON Syneos Health CMIC Group Labcorp   For additional details, please visit https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html   You may also be interested in the following titles: Gene Therapy Market: (5TH Edition) Industry Trends and Global Forecasts, 2022-2035 RNA Sequencing Services Market: Industry Trends and Global Forecasts, 2022-2035   About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.     Contact: Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com

Post the onset of the COVID-19 pandemic, mRNA therapeutics and vaccines have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as infectious diseases, oncological disorders, genetic disorders and other disorders.   mRNA therapeutics and vaccines have emerged as a promising alternative to conventional treatment approaches. During our research, we were able to identify more than 195 mRNA therapeutics and vaccines that have either been marketed or are being developed in clinical, preclinical and discovery stages for the treatment of various diseases. Driven by the growing interest of various stakeholders and encouraging clinical research results, the overall mRNA therapeutics and mRNA vaccines market is anticipated to witness consistent growth, till 2035.   To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market/request-sample.html   Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies. It is worth highlighting that there is a significant rise in the interest of stakeholders in mRNA vaccines domain segment; this can be validated by the increase in partnership and funding activity within this domain.   Given the numerous benefits of mRNA therapeutics and the increased demand for vaccines as a result of the recent COVID-19 pandemic, we believe that this market will experience significant growth in the near future. During our research, we came across around 180 ongoing and planned clinical trials focused on mRNA therapeutics and vaccines. There was a steady increase (CAGR of 66%) in the number of clinical trials registered for the evaluation of mRNA-based drugs, during the period 2017-2021. This can be attributed to the incessant efforts of several industry players that are actively evaluating mRNA therapies for the treatment of a myriad of disease indications. It is also worth highlighting that 47 trials were registered in 2022.   For additional details, please visit  https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html or email sales@rootsanalysis.com   You may also be interested in the following titles: RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035 Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035   About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

The success of currently employed artificial intelligence (AI) solutions has encouraged researchers to explore the potential of such technologies in the healthcare sector, with its prime focus being oncology, to enable the treatment of several prevalent malignancies.   London   Roots Analysis has announced the addition of “Artificial Intelligence in Oncology Market, 2022-2035” report to its list of offerings.   Several AI technologies demonstrating the potential to diagnose precancerous lesions are expected to be capable of reducing mortality rates by improving detection accuracy, speed and providing assistance in clinical decision-making. This is further expected to result in better clinical outcomes. Overall, this domain is anticipated to gain significant traction, in the foreseen future.   Key Market Insights   Over 76 companies claim to be engaged in the development of AI in oncology software solutions The AI in diagnostics market is dominated by companies based in North America, primarily in the US; of these, majority were established post 2010 and are small firms. Majority of the companies in this domain offer software solutions to hospitals (52%).   Nearly 2,770 patents have been filed / granted for AI based software solutions targeting oncology Reflecting the increasing research efforts of several industry players engaged in this domain, around 60% of the patents focused on the AI in oncology domain were filed / granted in North America, primarily in the US. It is also worth noting that the maximum patents were filed (69%) by non-academic players.    Partnership activity in this market has increased at a CAGR of 36% over the past five years   Technology integration agreements emerged as the most popular type of partnership model adopted by AI in oncology software solution providers, representing over 30% of the total instances. It is worth mentioning that 41% of the partnerships in this domain were inked in 2021.   USD 5.9+ billion has been invested by both private and public investors, since 2017 The maximum funding amount was raised through venture capital (66%), grants (11%) and seed funding (8%), during the period 2017-2022. Interestingly, around 86% of the funding instances were reported by players based in the US.   Europe is anticipated to capture over 30% of the global market share in 2035 In terms of cancer, the AI in oncology market for solid malignancies is likely to capture the maximum share (33%), followed by the share captured by breast cancer (30%), and this trend is unlikely to change in the foreseen future as well.   To request a sample copy / brochure of this report, please visit this  https://www.rootsanalysis.com/reports/ai-in-oncology-market/request-sample.html   Key Questions Answered Who are the leading players engaged in the development of AI in oncology-based software solutions? Which type of end-users are primarily employing AI in oncology-based software solutions in their regular workflow? What kind of partnership models are most commonly being adopted by stakeholders engaged in this domain? What is the trend for capital investments in this domain? What are the key strategies that can be implemented by emerging players / start-ups to enter into this highly competitive market? What is the focus area of big pharma players in this domain? Which companies are actively filing patents to drive innovation in the field of AI in oncology? What are the key challenges associated within this domain?   The financial opportunity within the AI in oncology market has been analyzed across the following segments: Type of Cancer  Solid Malignancies Breast Cancer Lung Cancer  Prostate Cancer  Colorectal Cancer  Brain Tumor  Others    Type of End-User Hospitals Pharma Companies  Research Institutes  Others     Key Geographical Regions  North America Europe Asia-Pacific  Rest of the world    The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:  Jon DeVries (Chief Executive Officer, Mirada Medical) Piotr Krajewski (Chief Executive Officer, CancerCenter.AI) Christian Vestergaard Kaltoft (Chief Executive Officer, Visiopharm) David Wilson (Vice President, Marketing and Communications, Enlitic) Emily Salerno (Commercial Strategy and Operations Lead, Nucleai)   The research includes detailed list of platforms being developed by key players (some of them are listed below); the report features an overview of the platform, details related to the AI technology employed, oncological indication targeted and information related to the type of platform (cloud-based, on-site). Ibex Medical Analytics Niramai Optellum Tempus Labs  Paige  Kheiron Medical Technologies    For additional details, please visithttps://www.rootsanalysis.com/reports/ai-in-oncology-market.htmlor email sales@rootsanalysis.com    You may also be interested in the following titles:  Targeted protein degradation market, 2022-2035 Cell Therapy Manufacturing Market,2021-2030 Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035                         About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.   Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors, offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors.     Roots Analysis has announced the addition of “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings.   Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential. In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing. The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes.     Key Market Insights   More than 140 stakeholders claim to manufacture viral and non-viral vectors The market is currently dominated by the presence of various mid-sized industry players (50%); of these 57% of players are contract manufacturers, whereas 22% of players are in-house manufacturers.   Over the time, severaladvancements have been made for the development of vector based technological platforms Majority (37%) of the available technologies are currently used in vector manufacturing followed by those available for manufacturing of cell and gene therapies (16%). Further, 53% of the vector-based technologies are dedicated for the development and manufacturing of adenoviral vectors.   More than 295 partnerships were established between different stakeholders during the last decade Close to 55% partnerships have been reported post 2018, wherein, maximum partnerships were recorded in year 2022 (till May). Further, maximum partnerships were related to manufacturing (23%) followed by licensing agreement (20%) and product development agreement (15%).   Close to 120 expansion activities have been recorded till 2022, growing at a CAGR of 10% Majority of the expansions in this domain were related to the establishment of new facility (39%) followed by facility expansion (12%).   The installed vector manufacturing capacity is estimated to be ~186,150 L Majority (70%) of total installed capacity is currently available for clinical / commercial stage manufacturing of viral vectors. Further, players headquartered in North America (56%) have the highest installed capacity, across the globe.   Till 2035, the annual demand for vectors is expected to grow at an annualized rate of 11% Currently, North America and Europe contribute to more than 70% of the demand for viral and non-viral vectors. By 2035, the demand, in terms of number of patients in clinical and commercial stage, demand for vectors, is projected to be ~ 400 thousand patients.    The market is anticipated to grow at a significant rate, during the period 2022-2035 The majority share of service revenues is anticipated to come from vector manufacturing projects focused on oncological disorders (51%). By 2035, Europe is likely to capture the major share (42%) of the market  followed by North America (30%) and Asia-Pacific (23%).   To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/274/request-sample.html     Key Questions Answered   Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of vectors and gene therapies? Which regions are the current manufacturing hubs for vectors and gene therapies? Which type of technologies are presently offered / being developed by the stakeholders engaged in this domain? Which companies are likely to partner with viral and non-viral vector contract manufacturing service providers? Which partnership models are commonly adopted by stakeholders engaged in this industry? What type of expansion initiatives are being undertaken by players in this domain? Which are the emerging viral and non-viral vectors used by players for the manufacturing of genetically modified therapies? What are the opportunities and threats for the stakeholders engaged in this industry? What is the current, global demand for viral and non-viral vector, and gene therapies? How is the current and future market opportunity likely to be distributed across key market segments?     By 2035, the financial opportunity within the viral vector, non-viral vector and gene therapy manufacturing market has been analyzed across the following segments: Scale of Operation Lab Clinical Commercial   Type of Vectors AAV Adenoviral Lentiviral Retroviral Plasmid DNA Other Vectors   Application Area Gene Therapy Cell Therapy Vaccines   Therapeutic Area Oncological Disorders Rare Disorders Neurological Disorders Sensory Disorders Metabolic Disorders Musco-skeletal Disorders Blood Disorders Immunological Diseases Others   Geographical Regions North America Europe Asia Pacific Latin America MENA Rest of the World   The report also features inputs from eminent industry stakeholders, according to whom, the anticipated increase in demand for cell and gene therapies, is the most prominent driver of the growth of the vector supply market. The report includes detailed transcripts of discussion held with prominent industry representatives:   Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences) Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals) Jeffrey Hung (Former Chief Commercial Officer, Vigene Biosciences) Cedric Szpirer (Former Executive & Scientific Director, Delphi Genetics) Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Former Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells) Alain Lamproye (Former President of Biopharma Business Unit, Novasep) Joost van den Berg (Former Director, Amsterdam BioTherapeutics Unit) Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital) Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes) Colin Lee Novick (Managing Director, CJ Partners) Semyon Rubinchik (Scientific Director, ACGT) Astrid Brammer (Senior Manager Business Development, Richter-Helm) Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Former Marketing Manager, Plasmid Factory) Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing) Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy) Nicolas Grandchamp (R&D Leader, GEG Tech) Géraldine Guérin-Peyrou (Director of Marketing and Technical Support, Polypus Transfection) Naiara Tejados, Head of Marketing and Technology Development, VIVEBiotech) Jeffery Hung (Independent Consultant)     The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), information related to its manufacturing facilities, proprietary vector manufacturing technology and an informed future outlook.:   Advanced BioScience Laboratories Aldevron Audentes Therapeutics BioNTech Innovative Manufacturing BioReliance Biovian bluebird bio Cell and Gene Therapy Catapult Celonic Centre for Process Innovation Cobra Biologics Emergent BioSolutions FinVector FUJIFILM Diosynth Biotechnologies Kaneka Eurogentec Lonza MeiraGTx MolMed Novasep Orchard Therapeutics Oxford BioMedica Richter-Helm Sanofi Spark Therapeutics Thermo Fisher Scientific uniQure Vibalogics Vigene Biosciences VIVEbiotech Wuxi AppTech   For additional details, please visit linkhttps://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html or email sales@rootsanalysis.com   You may also be interested in the following titles: 3D Cell Culture Market (4th Edition):  Industry Trends and Global Forecast, 2022-2035 Gene Therapy Market: Industry Trends and Global Forecast, 2022-2035   About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.   Contact: Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com